Prostaglandin E1 in Atherosclerosis

1. Front Matter

   Pages I-XII

   PDF

2. Pharmacological Actions of Prostaglandin E1

   1. Front Matter

      Pages 1-1

      PDF

3. Pharmacological Actions of Prostaglandin E1

   1. Biochemistry and Pharmacology of Prostaglandin E1: Introductory Remarks

      • R. Paoletti

      Pages 3-7

   2. On the Metabolism of Prostaglandin E1 in Patients Suffering from Arterial Occlusive Disease

      • Th. Simmet, B. A. Peskar, H. R. D. Wolf

      Pages 8-12

   3. Effects of Prostaglandins on Platelet Function Ex Vivo and in Animal Thrombosis Models

      • H. K. Breddin, W. Weichert

      Pages 13-21

   4. Different Effects of E- and l-Type Prostaglandins on Human Platelet and Polymorphonuclear Cell Function

      • K. Schrör, G. Hecker

      Pages 22-31

   5. The Effect of Intra-Arterial and Intravenous Prostaglandin E1 in a Model of Ischaemia in Healthy Volunteers

      • G. Rudofsky

      Pages 49-53

4. Pharmacological Actions of Prostaglandin E1

   1. Effects of Prostaglandin E1 on Low Density Lipoprotein Receptor Activity and Cholesterol Synthesis in Freshly Isolated Human Mononuclear Leukocytes

      • W. Krone, A. Klass, H. Nägele, B. Behnke, H. Greten

      Pages 32-38

   2. Inhibition of Mitotic and Proliferative Activity of Smooth Muscle Cells by Prostaglandin E1

      • H. Sinzinger

      Pages 39-48

5. Clinical Results with Prostaglandin E1

   1. Front Matter

      Pages 55-55

      PDF

6. Clinical Results with Prostaglandin E1

   1. Prospective Open Pilot Study to Investigate the Effect of Intermittent Intra-Arterial Infusion Treatment with Prostaglandin E1 in Patients with Intermittent Claudication

      • A. Creutzig, L. Caspary, K. Alexander

      Pages 57-65

   2. Treatment of Stage IIb Peripheral Arterial Occlusive Disease with Short-Term Intra-Arterial Infusion of Prostaglandin E1

      • W. Hach, B. W. Zanke, G. Sauerwein, Y. Özen

      Pages 66-74

   3. Clinical Efficacy of Intra-Arterial PGE1-Infusion in Intermittent Claudication: A Double-Blind Study

      • J. Blume, K. U. Rühlmann, H. Kiesewetter

      Pages 75-80

   4. Prostaglandin E1 in Arterial Occlusive Disease in Stages III and IV According to Fontaine

      • H.-P. Bruch, M. Hörl, A. Herold

      Pages 81-91

   5. Long-Term Intravenous Infusion of PGE1 in Peripheral Arterial Blood Flow Disorders: Results of an Open Screening Study with Patients in Fontaine’s Stages III and IV

      • H. Heidrich, H. Dimroth, M. Gutmann, J. Helmis, A. Peters, J. Ranft

      Pages 92-98

   6. Experiences with PGE1 in Patients with Phlegmasia Coerulea Dolens and in Ergotism

      • J. D. Gruss

      Pages 99-105

   7. PGE1 in Patients with Macular Degeneration

      • H. Heidrich, H. Harnisch, J. Ranft

      Pages 106-109

7. Back Matter

   Pages 111-112

   PDF

Prostaglandins were discovered in the early 1930s following research into their extremely potent biological effects. During the last decade especially two com­ pounds sharing the same receptor on the platelet surface, the antiaggregatory prostaglandins PGE and PGI , attracted considerable interest in cardiovascular 1 2 medicine. Since 1973 PGE has been widely used in the therapy of peripheral vascular 1 disease. Although its effects on platelet function, smooth muscle cells, vascular wall cell lipid metabolism, red cell deformability and plasmatic coagulation are well known, these factors altogether do not fully explain the efficacy of PG El in the therapy of advanced atherosclerosis. This book is the outcome of a workshop organised by Schwarz GmbH (Mon­ heim, FRG) which was held at Stresa, Italy, in April 1986. The coming together of researchers and clinicians produced a survey of the chemistry, physiology, pharmacology and clinical efficacy of PGE which will serve as a new insight 1 into the complexity of basic and clinical applications of PGE • 1 Helmut Sinzinger Waltraud Rogatti Table of Contents Pharmacological Actions of Prostaglandin E.

• atherosclerosis
• cardiovascular
• metabolism
• physiology
• platelet

• Atherosclerosis Research Group, University of Vienna, Wien, Austria

  Helmut Sinzinger

• Sanol Schwarz GmbH, Monheim, Federal Republic of Germany

  Waltraud Rogatti

Policies and ethics